Variable antibody-dependent activation of complement by functionalized phospholipid nanoparticle surfaces.
A wide variety of nanomaterials are currently being developed for use in the detection and treatment of human diseases. However, there is no systematic way to measure and predict the action of such materials in biological contexts. Lipid-encapsulated nanoparticles (NPs) are a class of nanomaterials that includes the liposomes, the most widely used and clinically proven type of NPs. Liposomes can, however, activate the complement system, an important branch of innate immunity, resulting in undesirable consequences. Here, we describe the complement response to lipid-encapsulated NPs that are functionalized on the surface with various lipid-anchored gadolinium chelates. We developed a quantitative approach to examine the interaction of NPs with the complement system using in vitro assays and correlating these results with those obtained in an in vivo mouse model. Our results indicate that surface functionalization of NPs with certain chemical structures elicits swift complement activation that is initiated by a natural IgM antibody and propagated via the classical pathway. The intensity of the response is dependent on the chemical structures of the lipid-anchored chelates and not zeta potential effects alone. Moreover, the extent of complement activation may be tempered by complement inhibiting regulatory proteins that bind to the surface of NPs. These findings represent a step forward in the understanding of the interactions between nanomaterials and the host innate immune response and provide the basis for a systematic structure-activity relationship study to establish guidelines that are critical to the future development of biocompatible nanotherapeutics.
Divisions of Rheumatology, Washington University School of Medicine, St. Louis, Missouri 63110, USA.
Christine T N
CT
Pham
Lynne M
LM
Mitchell
Jennifer L
JL
Huang
Christopher M
CM
Lubniewski
Otto F
OF
Schall
J Kendall
JK
Killgore
Dipanjan
D
Pan
Samuel A
SA
Wickline
Gregory M
GM
Lanza
Dennis E
DE
Hourcade
D000818:Animals; D000906:Antibodies / Q000276:immunology*; D003165:Complement System Proteins / Q000276:immunology*; D015195:Drug Design; D005682:Gadolinium / Q000737:chemistry; D006801:Humans; D007075:Immunoglobulin M / Q000276:immunology; D051379:Mice; D053769:Nanocapsules / Q000009:adverse effects / Q000737:chemistry*; D010743:Phospholipids; D013499:Surface Properties
D000906:Antibodies; D007075:Immunoglobulin M; D053769:Nanocapsules; D010743:Phospholipids; D003165:Complement System Proteins; D005682:Gadolinium